CURE’s 2019-2020 research initiative includes the following studies:
Research
Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta
Douglas Graham, MD, PhD
Aflac Cancer Center Precision Medicine Program
Robert Castellino, MD
PPM1D in High-Risk, Non-SHH, Non-WNT Medulloblastoma
Deborah DeRyckere, PhD
TAM Kinases as Mediators of Chemoresistance in AML
Lubing Gu, MD
Dual Inhibition of MDM2 and XIAP for Treatment of Childhood Cancers
Lisa Ingerski, PhD
HRQOL Outcomes During Molecularly Targeted Therapy for Brain Tumors
Christopher Porter, MD
Targeting Siglec15 for the Treatment of Childhood Cancers
Erwin Van Meir, PhD
Negative Regulation of b1-Integrin Signaling by ADGRB1 in Medulloblastoma
Muxiang Zhou, MD
MYCN Inhibition as a Precision Therapy in MYCN-amplified Neuroblastoma
Baylor College of Medicine
Alexandra Stevens, MD
A Trial of Atovaquone with Conventional Chemotherapy for Pediatric AML (ATACC AML)
Lisa L. Wang, MD
Optimizing GD2.CAR T Cell Immunotherapeutic Strategies for Relapsed Osteosarcoma and Neuroblastoma
Joanna Yi, MD
Defining the Transcriptional Control of Pediatric AML to Find New Drugs
Children’s Hospital of Philadelphia
Frank M. Balis, MD
GD2 as a Circulating Biomarker and Clinical Trial Endpoint for Neuroblastoma
Michael Chorny, PhD
Combination Therapy of Neuroblastoma Using Co-drug Impregnated Nanocarriers
Timothy Olson, MD, PhD
Bone Marrow Niche Targets to Prevent Cancer in Shwachman Diamond Syndrome
LLS PedAL Initiative, LLC
Soheil Meshinchi, MD, PhD
PedAL Initiative
Lurie Children’s Hospital of Chicago
Oren Becher, MD
Unraveling Mechanisms of Resistance to ACVR1 Inhibitors to Treat DIPG
Memorial Sloan Kettering Cancer Center
Estibaliz Lopez Rodrigo, MD
Lung Macrophage Synergy with L-MTP-PE to Target Metastatic Osteosarcoma.
Mt. Sinai Hospital
Zhihong Chen, PhD
Leveraging MMR Deficiency for Effective Immunotherapy in Childhood High-Grade Glioma
Stanford University
Maria-Grazia Roncarolo, MD
Innovative Cell Therapy for Pediatric AML
Kathleen Sakamoto, MD, PhD
Niclosamide for Relapsed/Refractory Pediatric AML
